COLOMBES, France - Samedi 23 Août 2014 [ME NewsWire]

(BUSINESS WIRE)--Oberthur Technologies, un leader mondial dans les solutions de sécurité numérique pour la mobilité, annonce ce jour qu’il présentera ses résultats financiers du second trimestre 2014 aux investisseurs le vendredi 29 août 2014.

Didier Lamouche (Directeur Général) et Anne-France Laclide (CFO) présenteront ces résultats financiers et répondront aux questions à 16h, heure de Paris.

Pour accéder aux informations concernant la téléconférence, merci de vous inscrire à l’adresse suivante : investors@oberthur.com

Si vous êtes déjà inscrits, tous les détails sont disponibles sur notre site internet : http://investors.oberthur.com

A PROPOS D’OBERTHUR TECHNOLOGIES

OT est un leader mondial dans les solutions de sécurité digitales pour la mobilité. OT a toujours été au cœur de la mobilité, depuis la première carte à puce aux dernières technologies de paiement san ... Read more »

COLOMBES, France - Friday, August 22nd 2014 [ME NewsWire]

(BUSINESS WIRE)-- Oberthur Technologies, a world leader in digital security solutions for the mobility space, today announced that it will present its second quarter 2014 financial results to investors on Friday August 29th, 2014.

Didier Lamouche (CEO) and Anne-France Laclide (CFO) will be presenting these financial results and taking questions the same day at 4pm CEST (3pm BST/ 10am EDT).

In order to access the conference call dial-in details, you need to register with Investor Relations: investors@oberthur.com.

If you have already registered, details are available on our website: http://investors.oberthur.com

ABOUT OBERTHUR TECHNOLOGIES

OT is a world leader in digital security solutions for the mobility space. OT has always been at the heart of mobility, from the first smart cards to the latest contactless payment technologies which equip millions of smartphones. Present in th ... Read more »

ME NewsWire/Business Wire

SUMMIT, N.J. - Thursday, August 21st 2014

Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.

In a phase II, open label, single arm study, by Dr. Grzegorz Nowakowski of the Mayo Clinic, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival (EFS) with secondary endpoints of progression free survival (PFS) and overall survival (OS). A one-stage binomial design was used t ... Read more »